{"id":"rizatriptan-benzoate-mk0462","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dyspepsia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action is not fully understood, but it is thought to involve the activation of 5-HT1B and 5-HT1D receptors, leading to the inhibition of pro-inflammatory neuropeptide release and vasoconstriction. This results in the relief of migraine headache symptoms.","oneSentence":"Rizatriptan benzoate is a selective serotonin 5-HT1B/1D receptor agonist, which is believed to relieve migraine headaches by causing vasoconstriction and inhibiting pro-inflammatory neuropeptide release.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:30.182Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute treatment of migraine attacks with or without aura"}]},"trialDetails":[{"nctId":"NCT06473597","phase":"PHASE4","title":"A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache","status":"RECRUITING","sponsor":"Antonios Likourezos","startDate":"2024-09-01","conditions":"Migraine","enrollment":80},{"nctId":"NCT00111722","phase":"PHASE3","title":"Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05-27","conditions":"Migraine","enrollment":393},{"nctId":"NCT00095004","phase":"PHASE3","title":"Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-10-21","conditions":"Migraine","enrollment":167},{"nctId":"NCT00111709","phase":"PHASE3","title":"Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05-27","conditions":"Migraine","enrollment":393},{"nctId":"NCT00092963","phase":"PHASE3","title":"Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-08-17","conditions":"Migraine","enrollment":529},{"nctId":"NCT00812006","phase":"PHASE3","title":"A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-03-24","conditions":"Migraine","enrollment":108},{"nctId":"NCT00516737","phase":"PHASE3","title":"Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-10-03","conditions":"Migraine","enrollment":207},{"nctId":"NCT01004263","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-12-01","conditions":"Acute Migraine With or Without Aura in Adolescents","enrollment":674},{"nctId":"NCT00604812","phase":"PHASE1","title":"Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-12-17","conditions":"Migraine Disorders","enrollment":31},{"nctId":"NCT00899379","phase":"PHASE3","title":"Treatment of Multiple Attacks of Acute Migraine (0462-025)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1995-04","conditions":"Migraine Headache","enrollment":473},{"nctId":"NCT00898677","phase":"PHASE3","title":"Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1995-09","conditions":"Migraine Headache","enrollment":1268},{"nctId":"NCT00897949","phase":"PHASE3","title":"MK0462 in Treatment of Migraine With Recurrence (MK0462-022)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1995-03","conditions":"Migraine Headache","enrollment":1473},{"nctId":"NCT00897104","phase":"PHASE3","title":"MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1995-08","conditions":"Migraine Headache","enrollment":933},{"nctId":"NCT00910689","phase":"PHASE4","title":"Drug and Non-Drug Treatment Of Severe Migraine","status":"COMPLETED","sponsor":"Ohio University","startDate":"2001-07","conditions":"Migraine Headache","enrollment":232}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MK0462"],"phase":"phase_3","status":"active","brandName":"rizatriptan benzoate (MK0462)","genericName":"rizatriptan benzoate (MK0462)","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rizatriptan benzoate (MK0462) is a small molecule serotonin 1b (5-HT1b) receptor agonist used to treat migraine headache. It is classified as an agonist and has been studied in clinical trials for the treatment of migraine with recurrence.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}